comparemela.com

Latest Breaking News On - Cellectis daily - Page 1 : comparemela.com

Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews com

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note published on Wednesday. The firm issued a sell rating on the biotechnology company’s stock. Cellectis Stock Performance NASDAQ CLLS opened at $2.71 on Wednesday. The stock has a 50-day simple moving average of $2.77 and a 200 day simple moving […]

Cellectis (NASDAQ:CLLS) Now Covered by StockNews com

Investment analysts at StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock. Cellectis Stock Performance Shares of Cellectis stock opened at $2.78 on Wednesday. The company has a quick ratio […]

Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews com

Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews com
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a report published on Monday. The brokerage issued a sell rating on the biotechnology company’s stock. Cellectis Price Performance Shares of CLLS opened at $3.04 on Monday. The firm has a market cap of $168.96 million, a price-to-earnings ratio of -1.77 and a […]

Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews com

Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews com
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.